The role of different LNG-IUS therapies in the management of adenomyosis: a systematic review and meta-analysis
- PMID: 39948612
- PMCID: PMC11823221
- DOI: 10.1186/s12958-025-01349-4
The role of different LNG-IUS therapies in the management of adenomyosis: a systematic review and meta-analysis
Abstract
Objective: To summarize evidence on the efficacy and safety of the levonorgestrel-releasing intrauterine system (LNG-IUS) in managing adenomyosis (AM), both as a monotherapy and in combination with other therapies.
Methods: We searched Medical Literature Analysis and Retrieval System On-Line: Medline, The Cochrane Library, Embase, SinoMed, China National Knowledge Infrastructure, and Wanfang from the inception to Aug 12, 2024 for articles using the LNG-IUS both alone and combined with other therapies in patients with AM. The primary outcome included dysmenorrhea, menstrual bleeding, uterine volume, endometrial thickness and quality of life. The secondary outcome was the assessment of adverse events. Data synthesis was conducted using random-effects model with significant heterogeneity (I2 > 50%), otherwise using fixed-effects model.
Results: The final analysis included 28 studies. Compared with etonogestrel, LNG-IUS was more effective in reducing uterine volume and associated with a lower risk of weight gain, but showed no significant difference in reducing dysmenorrhea and endometrial thickness. Comparing LNG-IUS with mifepristone, there was no significant difference in terms of quality of life. The combination of LNG-IUS with Gonadotropin-releasing hormone agonists (GnRH-a) was more effective than LNG-IUS alone, providing benefits in reducing dysmenorrhea (mean deviation, MD: -1.14), menstrual bleeding (MD: -11.94), uterine volume (MD: -30.39), endometrial thickness (MD: -0.89), and adverse events. The combination of LNG-IUS with surgical excision was more effective than surgical excision alone, providing benefits in reducing dysmenorrhea (MD: -1.49), menstrual bleeding (MD: -5.13) at 12 months, reducing uterine volume at 6 (MD: -9.23), 12 (MD: -16.53) and 24 (MD: -27.17) months. The combination of LNG-IUS with focused ultrasound ablation (FUA) was more effective than FUA alone, providing benefits in reducing dysmenorrhea (MD: -0.62), menstrual bleeding (MD: 0.17).
Conclusions: This study found no clear evidence to recommend single-drug therapy for improving pain and quality of life in AM management within 12 months. Combining LNG-IUS with GnRH-a is effective in alleviating pain, controlling heavy bleeding, reducing lesion volume, reducing the probability of expulsion and irregular bleeding. Postoperative LNG-IUS helps reduce long-term pain and bleeding. In combined FUA, LNG-IUS is effective for managing short-term pain and bleeding.
Trial registration: PROSPERO registration number: CRD42024578824.
Keywords: Adenomyosis; Efficiency; LNG-IUS; Safety; Treatment.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Figures


















Similar articles
-
Long-term efficacy and safety of levonorgestrel releasing intrauterine system in the treatment of adenomyosis: evidence mapping.Arch Gynecol Obstet. 2024 Jul;310(1):55-67. doi: 10.1007/s00404-024-07546-7. Epub 2024 Jun 5. Arch Gynecol Obstet. 2024. PMID: 38836931 Review.
-
Efficacy of high-intensity focused ultrasound combined with LNG-IUS for adenomyosis: a systematic review and meta-analysis.Arch Gynecol Obstet. 2023 Aug;308(2):351-362. doi: 10.1007/s00404-022-06720-z. Epub 2022 Aug 10. Arch Gynecol Obstet. 2023. PMID: 35947146
-
Progestogen-releasing intrauterine systems for heavy menstrual bleeding.Cochrane Database Syst Rev. 2020 Jun 12;6(6):CD002126. doi: 10.1002/14651858.CD002126.pub4. Cochrane Database Syst Rev. 2020. PMID: 32529637 Free PMC article.
-
Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.Cochrane Database Syst Rev. 2020 Sep 6;9(9):CD012658. doi: 10.1002/14651858.CD012658.pub2. Cochrane Database Syst Rev. 2020. PMID: 32909630 Free PMC article.
-
The treatment with Levonorgestrel Releasing Intrauterine System (LNG-IUS) in patients affected by menometrorrhagia, dysmenorrhea and adenomimyois: clinical and ultrasonographic reports.Eur Rev Med Pharmacol Sci. 2021 May;25(9):3432-3439. doi: 10.26355/eurrev_202105_25823. Eur Rev Med Pharmacol Sci. 2021. PMID: 34002816
Cited by
-
Development and validation of MRI-based radiomics model for clinical symptom stratification of extrinsic adenomyosis.Ann Med. 2025 Dec;57(1):2534521. doi: 10.1080/07853890.2025.2534521. Epub 2025 Jul 25. Ann Med. 2025. PMID: 40708430 Free PMC article.
References
-
- Leng J. Chinese experts’ consensus on diagnosis and treatment of adenomyosis. Chin J Obstet Gynecol. 2020;55:376–83. 10.3760/cma.j.cn112141-20200228-00150. - PubMed
-
- Xiong F, Li W, Rao X. Comparison of hysteroscopic electrotomy and curettagein the treatment of abnormal uterine bleeding caused byendometrial polyps. Contemp Med. 2021;27:88–90.
-
- Chinese Obstetricians and Gynecologists Association; Cooperative Group of Endometriosis, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Guideline for the diagnosis and treatment of endometriosis (third edition). Chin J Obstet Gynecol. 2021;56:812–24. 10.3760/cma.j.cn112141-20211018-00603.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources